| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 14.50 | 0.98 (+7.25%) | 9.86 - 31.21 | 6.7 million (Above Avg) |
Market data as of 4:00PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 13.40 |
|---|---|
| Previous Close | 13.52 |
| Day's Range | 13.12 - 15.04 |
| Market Cap | 1.5B |
| Avg Volume (10 Day) | 2.6M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.74 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
First Manhattan Adds Alex Denner to Vivus Board Slate
Business Wire - Thursday 05/23/2013 6:30 AM ET
First Manhattan Co. Releases Case for Full Board Change at Vivus
Business Wire - Tuesday 05/07/2013 4:15 PM ET
First Manhattan Files Preliminary Proxy Materials with SEC for the Election of Six Directors to Vivus’ Board at the 2013 Annual Meeting
Business Wire - Wednesday 05/01/2013 3:05 PM ET
First Manhattan Comments on Addition to Vivus’ Board of Directors
Business Wire - Wednesday 05/01/2013 8:34 AM ET
| VVUS | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 222.24 |
| Company | Last | Change |
|---|---|---|
| Alcobra Ltd | 7.21 | -4.50% |
| NPS Pharmaceuticals Inc | 15.25 | +2.01% |
| Acorda Therapeutics Inc | 32.23 | +0.47% |
| Immunogen Inc | 17.74 | +4.17% |
| Santarus Inc | 22.93 | +2.92% |
Data is delayed by at least 15 min.